Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms.

Multiple sclerosis (Houndmills, Basingstoke, England) - 1 Feb 2006

Frohman E M, Havrdova E, Levinson B, Slanar O

Abstract excerpt

We describe two multiple sclerosis patients who developed pancytopenia following treatment with azathioprine. They were found to have the homozygous polymorphism for thiopurine methyltransferase deficiency and recovered after cessation of drug therapy. We review the literature concerning this molecular derangement and underscore the importance of performing surveillance testing for allelic characterization prior...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Azathioprine
Share to Homozygote

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunosuppressive Agents

Share to Methyltransferases

Share to Multiple Sclerosis

Share to Pancytopenia

Share to Polymorphism, Genetic

Source

Identifiers

PMID: 16459728
DOI: 10.1191/135248506ms1249cr

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Azathioprine myelosuppression in multiple sclerosis: characterizing thiopurine methyltransferase polymorphisms.PMID 16459728Read ↗

Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.Semantic proximity Read ↗

The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics.Semantic proximity Read ↗

Normal thiopurine methyltransferase phenotype testing in a Crohn disease patient with azathioprine induced myelosuppression.Semantic proximity Read ↗

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients.Semantic proximity Read ↗

Azathioprine-related myelosuppression in a patient homozygous for TPMT*3A.Semantic proximity Read ↗

Thiopurine S-Methyltransferase Polymorphisms Predict Hepatotoxicity in Azathioprine-Treated Patients with Autoimmune DiseasesSemantic proximity Read ↗

High frequency of mutant thiopurine S-methyltransferase genotypes in Mexican patients with systemic lupus erythematosus and rheumatoid arthritis.Semantic proximity Read ↗

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?Semantic proximity Read ↗

Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from AzathioprineSemantic proximity Read ↗

Genetic polymorphisms of thiopurine S-methyltransferase in a cohort of patients with systemic autoimmune diseases.Semantic proximity Read ↗

Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.Semantic proximity Read ↗

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.